London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is embarking on a pivotal clinical study ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

Deutsche Bank Research raises London Stock Exchange price target to 11,900 (11,500) pence - 'buy' Deutsche Bank Research raises Reckitt Benckiser price target to 5,700 (5,600) pence - 'hold' Comments ...

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has announced the purchase of 555,000 of its own ordinary shares as part ...

The China National Medical Products Administration (NMPA) has approved Shingrix (GSK's Recombinant Zoster Vaccine or RZV) for ...